Leerink Partners on Abivax (ABVX): 'Key Clinical & Regulatory Catalysts on Track'
Tweet Send to a Friend
Leerink Partners analyst Thomas Smith reiterated an Outperform rating and $138.00 price target on Abivax (NASDAQ: ABVX).The analyst comments "ABVX ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
